The recommended dose of crizotinib is 250 mg orally twice daily, taken just after breakfast and dinner. Crizotinib capsules can be used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer that is kinase-positive in mesenchymal lymphoma. The recommended dosage of this product is 250mg once in the morning and once in the evening, with meals, until disease progression or patient intolerance. For patients with severe renal impairment who do not require dialysis, 250mg once, once after breakfast is sufficient. The common adverse reactions of this product include diarrhea, vomiting, visual abnormalities, nausea, edema, constipation, elevated aminotransferases, fatigue, loss of appetite, etc. It is contraindicated in patients who are allergic to this product and in patients with severe hepatic impairment. Please use the drug according to the doctor’s instructions under the guidance of a physician, not blindly self-medication.